JT Signs an Exclusive License Agreement with Dermavant to Develop and Commercialize Tapinarof in Japan

 JT Signs an Exclusive License Agreement with Dermavant to Develop and Commercialize Tapinarof in Japan

JT Signs an Exclusive License Agreement with Dermavant to Develop and Commercialize Tapinarof in Japan

Shots:

  • Dermavant to receive $60M up front, up to $53M as development milestones and royalties on sales of the tapinarof in psoriasis and AD. JT and its subsidiary, Torii Pharmaceutical to get rights to develop & commercialize tapinarof for psoriasis and AD in Japan
  • Additionally, JT has signed an exclusive license agreement with Torii to co-develop and commercialize tapinarof in Japan
  • Tapinarof (qd) is an investigational therapeutic aryl hydrocarbon receptor modulating agent (TAMA), currently being evaluated in two P-III studies for psoriasis in the US and P-II studies for both psoriasis and AD with its expected NDA filing for PsO to the US FDA in 2021

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: Cmocro

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post